Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.59 |
| ▸ | METAP2 | P50579 | 3/20 | 0.57 |
| ▸ | METAP1 | P53582 | 1/20 | 0.57 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986006 | 0.80 | METAP2 (0.62) | METAP2METAP1LMNATSHRALDH1A1 | |
| SCHEMBL3980755 | 0.79 | METAP2 (0.58) | ACLYMETAP2 | |
| SCHEMBL3987257 | 0.77 | METAP2 (0.60) | ACLYMETAP2METAP1LMNAGAA | |
| SCHEMBL17599327 | 0.76 | ACLY (0.61) | ACLYCCR2MCL1TSHRSGK1 | |
| SCHEMBL4277652 | 0.76 | METAP2 (0.69) | METAP2METAP1MCL1GAATSHR | |
| SCHEMBL17599305 | 0.75 | ACLY (0.55) | ACLYCCR2MCL1LMNATSHR | |
| SCHEMBL21931025 | 0.74 | ACLY (1.00) | ACLYMCL1 | |
| SCHEMBL3986500 | 0.74 | METAP2 (1.00) | METAP2METAP1MCL1LMNAGAA | |
| SCHEMBL3984291 | 0.73 | METAP2 (0.82) | METAP2METAP1LMNACYP1A2MAPT | |
| SCHEMBL3985677 | 0.73 | METAP2 (0.82) | METAP2METAP1CCR2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | ACLY 2986/4885METAP2 1/4885METAP1 2/4885 |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | ACLY 2986/4885METAP2 1/4885METAP1 2/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | ACLY 2986/4885METAP2 1/4885METAP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.